Maximo Marin

Dr. Maximo Marin


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2021 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
NHNeil Harris
Neil Harris
JPJ. Peter Pelletier
J. Peter Pelletier
MMMaximo Marin
Maximo Marin
WWWilliam Winter
William Winter
Given that von Willebrand disease (VWD) is one of the most common bleeding disorders, the diagnosis or the exclusion is essential in the workup of individuals that have unexplained bleeding. For the clinical laboratory, the challenge is highlighted by the variable presentations of this disorder and the multiple assays that are available from different vendors. This review will give a brief overview of primary hemostasis with a detailed explanation of the biosynthesis, structure, and mechanics of von Willebrand factor (VWF). The final sections will focus on the distinguishing characteristics of the different types of VWD and the array of clinical laboratory tests currently available to assist in the diagnosis.

22 April 2024 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Closed access
PDF file
MMMaximo Marin
Maximo Marin
XWXander M R van Wijk
Xander M R van Wijk
PBPaul D Boothe
Paul D Boothe
NHNeil Harris
Neil Harris
WWWilliam E Winter
William E Winter
Background: The most frequently ordered laboratory test worldwide is the complete blood count (CBC). Content: In this primer, the red blood cell test components of the CBC are introduced, followed by a discussion of the laboratory evaluation of anemia and polycythemia. Summary: As clinical chemists are increasingly tasked to direct laboratories outside of the traditional clinical chemistry sections such as hematology, expertise must be developed. This review article is a dedication to that effort.

28 January 2025 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Closed access
BOBremansu Osa-Andrews
Bremansu Osa-Andrews
XWXander M R van Wijk
Xander M R van Wijk
NRNormarie Herrera Rivera
Normarie Herrera Rivera
RSRobert P Seifert
Robert P Seifert
NHNeil Harris
Neil Harris
MMMaximo Marin
Maximo Marin
Background: The most frequently ordered laboratory test worldwide is the complete blood count (CBC). As clinical chemists are increasingly assigned to assist or direct laboratories outside of the traditional clinical chemistry sections, such as the automated hematology section, expertise must be established. This review article is a dedication to that ongoing effort. Content: In this primer, the white blood cell (WBC) test components of the CBC are introduced, followed by a discussion of the laboratory evaluation of leukopenia and leukocytosis. Summary: The laboratorian's approach to consult cases should be guided by the patient's clinical history and presentation while being able to provide key laboratory-based insights to assist in resolving result discrepancies that may otherwise go unnoticed.

30 March 2022 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
MMMaximo Marin
Maximo Marin
XWXander M R Van Wijk
Xander M R Van Wijk
TDThomas J S Durant
Thomas J S Durant
As healthcare continues to undergo a digital transformation, there has been a concurrent and rapid rise in the number of Food and Drug Administration (FDA)-cleared artificial intelligence (AI) and machine learning (ML) enabled medical devices. At the time of this writing, there are 343 FDA-cleared devices, 93% of which were introduced after 2014 ( Fig. 1). Of these, there are approximately 20 FDA-cleared medical devices that are intended for use in clinical laboratories. As this trend is expected to continue, there is an urgent need for consensus development standards and dedicated approval pathways for AI/ML-enabled medical devices, both of which do not currently exist either domestically or internationally. In October 2021, the FDA, Health Canada, and the UK’s Medicines and Healthcare products Regulatory Agency jointly published 10 guiding principles to promote safe, effective, and high-quality medical devices that leverage AI/ML technology (Good Machine Learning Practice; GMLP) ( 1). This represents another incremental step toward the goal of harmonizing best practices and a national regulatory framework for devices that leverage AI/ML. The principles that are outlined in the document address practices related to DataOps (i.e., data operations) and MLOps (i.e., ML operations), end-user interface design, device validation, and performance monitoring during pre- and postdeployment phases.

29 March 2024 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Closed access
PDF file
XWXander M R van Wijk
Xander M R van Wijk
ZOZaraith Sanchez Oviol
Zaraith Sanchez Oviol
WWWilliam E Winter
William E Winter
NHNeil Harris
Neil Harris
MMMaximo Marin
Maximo Marin
Background: The most ordered laboratory test worldwide is the complete blood count (CBC). Content: In this primer, an introduction to platelet testing in the context of the CBC is provided with a discussion of the laboratory evaluation of platelet abnormalities including thrombocytopenia and thrombocytosis. Summary: As clinical chemists continue to be tasked to direct laboratories outside of the traditional clinical chemistry sections such as hematology, expertise must be developed. This primer is dedicated to that effort.

4 May 2025 in Laboratory Medicine
Verified
Journal Article
Closed access
NHNeil Harris
Neil Harris
MMMaximo Marin
Maximo Marin
SBSaulius Butenas
Saulius Butenas
The steps that initiate coagulation in vivo are different from the components of prothrombin time (PT) and activated partial thromboplastin time (aPTT). The reactions of PT and aPTT are kept separate by the addition of high concentrations of tissue factor (for PT) or silica (for aPTT). In vivo, these reactions blend together as an initiation phase followed by a propagation phase. The initiation phase produces small quantities of thrombin, while much larger amounts of thrombin are generated by the propagation phase. Formation of a visible clot occurs when less than 4% of the total thrombin is generated. Although the contact pathway is essential for the aPTT reaction, this set of reactions does not play a role in normal hemostasis in vivo but does appear to be important in pathologic thrombosis and inflammation. The hemostatic pathways are controlled in vivo by the antithrombin system, tissue factor pathway inhibitor, and the protein C and protein S complexes. Platelets and endothelial cells are an essential component of hemostasis. In the presence of thrombin and vessel wall damage, platelets are activated, and they adhere to the bleeding site and aggregate releasing other mediators for further platelet aggregation.